Ország: Írország
Nyelv: angol
Forrás: HPRA (Health Products Regulatory Authority)
Trimipramine
Sanofi-Aventis Ireland Limited T/A SANOFI
N06AA; N06AA06
Trimipramine
25 milligram(s)
Film-coated tablet
Product subject to prescription which may not be renewed (A)
Non-selective monoamine reuptake inhibitors; trimipramine
Not marketed
1978-04-01
SURMONTIL 25MG FILM‐COATED TABLETS _Trimipramine _ _ _ PACKAGE LEAFLET: INFORMATION FOR THE USER IS THIS LEAFLET HARD TO SEE OR READ? PHONE 01 403 5600 FOR HELP READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. IN THIS LEAFLET: 1. What Surmontil Tablets are and whatthey are used for 2. What you need to know before you take Surmontil Tablets 3. How to take Surmontil Tablets 4. Possible side effects 5. How to store Surmontil Tablets 6. Contents of the pack and other information 1. WHAT SURMONTIL TABLETS ARE AND WHAT THEY ARE USED FOR The name of your medicine is Surmontil 25mg Film‐coated Tablets (called Surmontil Tablets in this leaflet). Surmontil Tablets contain a medicine called trimipramine (as maleate). This belongs to a group of medicines called antidepressants. Surmontil Tablets can be used to treat depression. They are especially useful for treating depression in people who also have problems sleeping, stress (anxiety) or feel irritable and restless (agitation). 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE SURMONTIL TABLETS DO NOT TAKE THIS MEDICINE AND TELL YOUR DOCTOR IF: • You are allergic (hypersensitive) to trimipramine or any of the other ingredients of Surmontil Tablets (listed in Section 6 Further information). Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue • You are hypersensitive to other tricyclic antidepressants • if you have recently had a heart attack • You have any other heart problems including slow or uneven heart beat • You have severe liver problems • In Olvassa el a teljes dokumentumot
Health Products Regulatory Authority 20 February 2023 CRN00C7K9 Page 1 of 9 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Surmontil 25mg film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Trimipramine Maleate equivalent to 25 mg of Trimipramine. Excipients: each tablet contains 4.32 mg lactose monohydrate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. White to pale yellow, circular, biconvex, film-coated tablet, one face impressed “SURMONTIL” just inside the perimeter around a centrally impressed ‘25’, reverse face plain. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Surmontil has a potent antidepressant action similar to that of other tricyclic antidepressants. It also possesses a pronounced sedative action. It is therefore indicated in the treatment of depressive illness, especially where sleep disturbance, anxiety, or agitation are presenting symptoms. Sleep disturbance is controlled within 24 hours and true antidepressant action follows within 7 to 10 days. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The route of administration is oral. Recommended Dosage: Depression: _Adults:_ The usual daily dose is 50 - 100 mg daily as a single dose, 2 hours before retiring. In more severe depression, dosage should be increased gradually until the optimum therapeutic response is achieved (usually 150 - 300 mg daily) then reduced after 4-6 weeks to a maintenance level of 75 - 150 mg daily. _Elderly:_ Initially, a low dosage is recommended, generally half the minimum recommended dose (see Pharmacokinetic Data). Increasing dosage, if required, must take place gradually under clinical supervision: the side effects of imipramines may have serious consequences in elderly patients (falls, confusion). _Paediatric Population:_ Surmontil should not be used in the treatment of children or adolescents under the age of 18 years (see section 4.4 and 4.8). _Patients with hepatic or renal insufficiency:_ In patients with hepatic an Olvassa el a teljes dokumentumot